

transfected target cells. These assays identified four CTL epitopes within the capsid, E1, and E2 regions of the polyprotein sequence of HCV genotype 1a that were cross-reactive with HCV genotype 1b. Additionally, CTLs derived from mice immunized with either NS3 or NS5 specifically lysed target cells sensitized to either the genotype 1a or 1b gene products. **Nucleic acid immunizations** also generated humoral immunity to HCV proteins, as detected by anti-HCV reactivity to NS3 and capsid in ELISAs and immunoblot assays.

112 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:67112 CAPLUS
 DOCUMENT NUMBER: 124:108965
 TITLE: Nucleic acid immunization using a virus-based infection/transfection system
 INVENTOR(S): Selby, Mark; Walker, Christopher
 PATENT ASSIGNEE(S): Chiron Corp., USA
 SOURCE: PCT Int. Appl., c3 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533835	A1	19951214	WO 1995-US6809	19950531
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2191362	AA	19951214	CA 1995-2191362	19950531
AU 9526862	A1	19960104	AU 1995-26862	19950531
EP 802980	A1	19971029	EP 1995-921498	19950531
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE			
JP 10501136	T2	19980203	JP 1995-501128	19950531
US 6385247	B1	20020312	US 1996-737061	19961104
PRIORITY APPLN. INFO.:			US 1994-252961	A2 19940602
			WO 1995-US6809	W 19950531

AB A method for nucleic acid immunization which results in a cell-mediated immunol. response to a selected antigen is disclosed. The method utilizes the T7 RNA infection/transfection system which provides for the controlled, transient cytoplasmic expression of a given antigen and which elicits the prodn. of class I MHC restricted cytotoxic T-lymphocytes. Thus, the subject is subjected to two constructs. First, the T7 RNA polymerase gene is used via a viral vector (e.g., an avipoxvirus or vaccinia virus). The second construct consists of a recombinant vector comprising the coding sequence for the desired antigen operably linked to the bacteriophage T7 promoter; the vector may be encapsulated in a liposome. Illustrative immunizations are demonstrated using vectors expression the hepatitis C virus envelope glycoprotein E2 or the human immunodeficiency virus glycoprotein gp120env. The construct bearing the gene of interest and the vector including the T7 RNA polymerase gene can be used individually or in combination in vaccine compns.

-> d his

FILE 'HOME' ENTERED AT 14:01:22 ON 16 MAR 2002

FILE 'MEELINE, CAPLUS, USPATFULL, BIOLOG, EMPBASE' ENTERED AT 14:05:59 ON 16 MAR 2002

11 127 2 HEPATITIS VIRUS C
 12 63847 2 HEPATITIS C VIRUS

$\Rightarrow \log_{\frac{1}{2}} 16$ hold

L Number	Hits	Search Text	DB	Time stamp
-	3174	hepatitis ADJ c	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:10
-	3174	hepatitis ADJ c or hepatitis ADJ c ADJ virus	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:10
-	369	ns4 or ns5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:11
-	101	(hepatitis ADJ c or hepatitis ADJ c ADJ virus) same (ns4 or ns5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12 10
-	272	ns4 or ns5.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12 11
-	14	ns4.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12 11
-	14	ns5.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12 12
-	79067	nucleic acid and ns5.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:13
-	10	nucleic ADJ acid and ns5.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:16
-	9	hepatitis ADJ c and nucleic ADJ acid and ns5.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/03/18 12:16